Risk of skin cancer in the drug treatment of rheumatoid arthritis

Expert Opinion on Drug Safety

Volumn 7, Issue 5, 2008, Pages 539-546

  Chakravarty, Eliza F ^a   Farmer, Evan R ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug therapy; Melanoma; Methotrexate; Non melanoma skin cancer; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; CONDYLOMA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; GENE MUTATION; HEREDITY; HUMAN; LINKAGE ANALYSIS; MELANOMA; MERKEL CELL TUMOR; MONOTHERAPY; OBSERVATIONAL STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SKIN CANCER; SMOKING CESSATION; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION; INCIDENCE; SKIN TUMOR;

ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; MELANOMA; RISK FACTORS; SKIN NEOPLASMS;

EID: 54449101092     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.5.539     Document Type: Review

References (57)

1. Naz SM, Symmons DPM. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21:871-83
2. Chakravarty EF, Genovese MC. Associations between rheumatoid arthritis and malignancy. Rheum Dis Clin North Am 2004;30:271-84
3. Bernatsky S, Clarke A, Suissa S. Lung cancer after exposure to disease modifying anti-rheumatic drugs. Lung cancer 2008;59:266-9
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
5. Coory M, Baade P, Aitken J, et al. Trends for in situ and invasive melanoma in Queensland Australia, 1982-2002. Cancer Causes Control 2006;17:21-7
6. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975 - 2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119-52
7. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century. Part I. Epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007;82:364-80
8. Fortes C, de Vries E. Nonsolar occupational risk factors for cutaneous melanoma. Int J Dermatol 2008;47:319-28
9. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992 - 2003. Ann Intern Med 2008;148:728-36
10. Hollenbeak CS, Todd MM, Billingsley EM, et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005;104:1962-7
11. Webster AC, Craig JC, Simpson JM, et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15, 183 recipients. Am J Transplant 2007;7:2140-51
12. Le Mire L, Hollowood K, Gray D. Melanomas in renal transplant recipients. Br J Dermatol 2006;154:472-7
13. Katusic S, Beard CM, Kurland LT, et al. Occurrence of malignant neoplasms in the Rochester, Minnestota Rheumatoid Arthritis Cohort. Am J Med 1985;78:50-5
14. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11
15. Mellemkjær L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7
16. Thomas E, Brewster DH, Black RJ, MacFarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502
17. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6
18. Setoguchi S, Soloman DH, Weinblatt ME, et al. Tumor necrosis factor a antagonist use and cancer in patients with rheumatoid arthritis. Arthrids Rheum 2006;54:2757-64
19. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 207;56:2886-95
20. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9
21. Hemminki K, Li X, Sundquist K, et al. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford) 2008;47:698-701
22. Abasolo L, Judez E, Descalzo MA, et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008;37:388-97
23. Jeannou J, Goupille P, Valat JP. Association of methotrexate, rheumatoid arthritis, and melanoma in 2 patients [letter]. J Rheumatol 1997;24:1444-5
24. Potter T, Hardwick N, Mulherin D. Multiple malignant melanomas in a patient with RA treated with methotrexate [letter]. J Rheumatol 1998;25:2282-3
25. Bologna C, Picot MC, Jorgensen C, et al. Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate. Ann Rheum Dis 1997;56:97-102
26. Fulcherio GJ, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56:S65-7
27. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275-85
28. Edwards JCW, Szczepaniski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
29. Cohen SB, Emery P, Greenwald GW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806
30. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Int Med 2006;144:865-76
31. Chuang TY, Popescu A, Su WP, Chute CG. Basal cell carcinoma. A population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol 1990;22:413-7
32. Reizner GT, Chuang TY, Elpern DJ, et al. Basal cell carcinoma in Kauai, Hawaii: the highest documented incidence in the United States. J Am Acad Dermatol 1993;29(2 Pt 1):184-9
33. Staples MP, Elwood M, Burton RC, et al. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006;184:6-10
34. Chuang TY, Popescu NA, Su WP, Chute CG. Squamous cell carcinoma. A population-based incidence study in Rochester, Minn. Arch Dermatol 1990;126:185-8
35. ChuangTY, Reizner GT, Elpern DJ, et al. Squamous cell carcinoma in Kauai, Hawaii. Int J Dermatol 1995;34:393-7
36. Wei Q, Matanoski GM, Farmer ER, et al. DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl Acad Sci USA 1993;90:1614-8
37. Freidman GD, Tekawa IS. Association of basal cell skin cancers with other cancers (United States). Cancer Causes Control 2000;11:891-7
38. Efird JT, Friedman GD, Habel L, et al. Risk of subsequent cancer following invasive or in situ squamous cell skin cancer. Ann Epidemiol 2002;12:469-75
39. Lupi O. Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int J Dermatol 2007;46:1113-7
40. Asgari MM, Kiviat NB, Critchlow CW, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008;128:1409-17
41. Bouwes Bavinck JN, Plasmeijer EI, Feltkamp MC. Beta-papillomavirus infection and skin cancer. J Invest Dermatol 2008;128:1355-8
42. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001;63:8-18
43. Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol 2008;58(5 Suppl 2):S129-32
44. Euvard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91
45. Ho WL, Murphy GM, Update on the pathogenesis of post-transplant skin cancer in renal transplant recipients. Br J Dermatol 2008;158:217-24
46. Crespo-Leiro MG, Alonso-Pulpon L, Vazquez de Prada JA, et al. Malignancy after heart transplantation: incidence, prognosis, and risk factors. Am J Transplant 2008;8:1031-9
47. Vasudev B, Hariharan S. Cancer after renal transplantation. Curr Opin Nephrol Hypertens 2007;16:523-8
48. Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985 - 1998. Br J Cancer 2003;89:94-100
49. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997;40(9):1580-6
50. Chakravarty ER, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5
51. Dixon W, Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and infection? Arthritis Res Ther 2006;8:111-3
52. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
53. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor receptor IgG1-Fx fusion complex therapy. J Am Acad Dermatol 2001;45:953-6
54. Esser AC, Abril A, Fayne S, Doyle JA. Acute development of multiple keratocanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004;50(Suppl 5):S75-7
55. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and non-biologic disease modifying antirheumatic drugs. Arthritis Rheum 2006;54:2807-16
56. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept. Arthritis Rheum 2005;52:2263-71
57. Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 2007;82:1106-9